Status:
COMPLETED
Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia
Lead Sponsor:
University of New Mexico
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Pterygium
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Ranibizumab, an effective antineovascular drug, will be studied for safety and efficacy in pterygium, a neovascular disorder of the ocular surface.
Detailed Description
Ptergyia are chronic fibrovascular lesions of the ocular surface. This study is designed to look for a signal of efficacy when the lesions are in a phase of active vascular growth. This phase is most ...
Eligibility Criteria
Inclusion
- Patients with actively growing pterygia, either surgical recurrences, or non-surgical primary lesions.
Exclusion
- Pregnancy
- History of CVA
- Monocular patients
- Minors
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01169909
Start Date
August 1 2010
End Date
July 1 2014
Last Update
May 17 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of New Mexico Health Science Center
Albuquerque, New Mexico, United States, 87106